The Pentagon on Thursday reported a $342 million agreement that has been granted to British pharmaceutical goliath GlaxoSmithKline to convey "mass amounts of COVID-19 antibodies" to US troops.

It said GSK was the main organization to make an offer for the agreement, which will comprise of supporting "military areas and staff all through the mainland US and outside the mainland US."

The work will be done in North Carolina "with an expected finish date of Feb. 28, 2021," the Pentagon said.

The US Army will manage the execution of the venture.